Pharmaceutical News

RSS

Stimulant use linked with increased risk of cardiovascular events among older adults in the first month

New research led by Mina Tadrous, Assistant Professor, Leslie Dan Faculty of Pharmacy, University of Toronto shows that use of prescription stimulant medications in older adults increased the risk of a cardiovascular events by 40 per cent within the first thirty days of medication use.

25 Oct 2021

A comparison between Pfizer/BioNTech's and Sinopharm's SARS-CoV-2 vaccines

Researchers compare antibody titers elicited the Pfizer‐BioNTech mRNA and the classic inactivated virus Sinopharm vaccines.

24 Oct 2021

Does previous SARS-CoV-2 infection affect vaccine-induced immunity?

Researchers report the binding and pseudo-neutralizing antibody titers elicited after patients had received either the Pfizer-BioNTech or AstraZeneca vaccines.

24 Oct 2021

Vaccination data from Puerto Rico strongly supports COVID19 booster shots

In a recent study, researchers from the U.S. examined the vaccine effectiveness against SARS-CoV-2 infections in Puerto Rico.

24 Oct 2021

Antidepressant offers no improvement in agitation for people with dementia, study shows

A drug used to treat agitation in people with dementia is no more effective than a placebo, and might even increase mortality, according to a new study.

22 Oct 2021

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021

Comparative effectiveness of ChAdOx1 and BNT162b2 COVID-19 vaccines

In a recent study, researchers compared the efficacy of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines against infection SARS-CoV-2.

21 Oct 2021

Antidepressant Prozac could offer the first treatment for atrophic macular degeneration

An antidepressant best known as Prozac could offer the first treatment for the leading cause of blindness among people over 50, new research from the University of Virginia School of Medicine suggests.

21 Oct 2021

Researchers employ novel algorithm to identify candidate cancer drugs for pulmonary hypertension

By combining computational and experimental approaches, University of Pittsburgh School of Medicine and Prairie View A&M University researchers identified cancer drugs that show promise for treating pulmonary hypertension, or PH, a rare and incurable lung disease.

21 Oct 2021

Drug company pipelines are filling up with new molecules to help people lose weight

Drugs that promise to help people lose weight have had a checkered past, such as the infamous fen-phen that was pulled from the market in 1997 after reports of heart valve damage. But now, drug company pipelines are filling up with new molecules that aim to help people safely shed extra pounds, according to a cover story in Chemical & Engineering News, an independent news outlet of the American Chemical Society.

21 Oct 2021

How the public views COVID-19 vaccines via Twitter in the United States

A new study uses Twitter to examine public attitudes towards the vaccines developed to fight the COVID-19 in the United States.

20 Oct 2021

New research on phagocytosis and SARS-CoV-2's spike protein

A new study showed that convalescent patient plasma and monoclonal anti-spike antibodies were able to induce phagocytosis at high antibody concentrations.

20 Oct 2021

Commonly prescribed medications can make the flu virus more or less active

Although the influenza virus varies a lot from year to year, the flu usually contributes to approximately 1000 deaths a year in Norway.

19 Oct 2021

Nasal delivery of single-domain antibodies improves SARS-CoV-2 symptoms in animal model

In a recent study published in the journal PLOS Pathogens, scientists showed that nasal administration of a single-domain antibody (VHH), named K-874A, brought about inhibition of SARS-CoV-2 titers in infected lungs of Syrian hamsters.

19 Oct 2021

Scientists scan 110 natural compounds for SARS-CoV-2 antiviral potential

Phytochemicals are plant-derived molecules from medicinal plants that act as a prominent reservoir for treating a wide range of viral infections. In a new study, published in the journal Scientific Reports, scientists adopted a computational approach to identify Mpro inhibitors.

19 Oct 2021

Waning COVID vaccine efficacy especially against reinfection

A new study in American veterans posted to the medRxiv* preprint server suggests severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are less effective in preventing infection after six months. The decline was most significant with the Johnson & Johnson vaccine, with vaccine effectiveness plummeting from 88% to 3%.

19 Oct 2021

Factors contributing to a weak antibody response to the Pfizer COVID-19 vaccine

A new study discusses risk factors for the failure of seroconversion following full vaccination with the COVID-19 Pfizer vaccine.

18 Oct 2021

Watch: Going beyond the script of ‘Dopesick’ and America’s real-life opioid crisis

KHN and policy colleagues at our parent organization KFF teamed up with Hulu for a discussion of America’s opioid crisis, following the Oct. 13 premiere of the online streaming service's new series "Dopesick."

18 Oct 2021

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological processes such as cancer and inflammatory diseases. A natural fragment of serum albumin, named EPI-X4, has previously been identified as endogenous peptide antagonist andinverse agonistof CXCR4 and is a promising compound for the development of improved analogues for the therapy of CXCR4-associated diseases.

18 Oct 2021

Researchers identify common side effects of three COVID-19 vaccines

COVID-19 vaccines remain the best tool in the pandemic toolbox against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). But they are not perfect; reports have surfaced of mild to severe side effects after vaccination. A new study from researchers in the Lampe & Company GmbH & Co. KG compared the severity of adverse events from each coronavirus vaccine.

17 Oct 2021

Pharmaceutical News

Stimulant use linked with increased risk of cardiovascular events among older adults in the first month

A comparison between Pfizer/BioNTech's and Sinopharm's SARS-CoV-2 vaccines

Does previous SARS-CoV-2 infection affect vaccine-induced immunity?

Vaccination data from Puerto Rico strongly supports COVID19 booster shots

Antidepressant offers no improvement in agitation for people with dementia, study shows

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Comparative effectiveness of ChAdOx1 and BNT162b2 COVID-19 vaccines

Antidepressant Prozac could offer the first treatment for atrophic macular degeneration

Researchers employ novel algorithm to identify candidate cancer drugs for pulmonary hypertension

Drug company pipelines are filling up with new molecules to help people lose weight

How the public views COVID-19 vaccines via Twitter in the United States

New research on phagocytosis and SARS-CoV-2's spike protein

Commonly prescribed medications can make the flu virus more or less active

Nasal delivery of single-domain antibodies improves SARS-CoV-2 symptoms in animal model

Scientists scan 110 natural compounds for SARS-CoV-2 antiviral potential

Waning COVID vaccine efficacy especially against reinfection

Factors contributing to a weak antibody response to the Pfizer COVID-19 vaccine

Watch: Going beyond the script of ‘Dopesick’ and America’s real-life opioid crisis

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

Researchers identify common side effects of three COVID-19 vaccines

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News